Journal of Oncology / 2008 / Article / Tab 3

Clinical Study

CYP1A1, mEH, and GSTM1 Polymophisms and Risk of Oral and Pharyngeal Cancer: A Spanish Case-Control Study

Table 3

Risks for the different polymorphisms broken down by smoking categories.

Genetic polymorphism Cases Controls OR crude OR adjusted

Light/moderate smokers (≤35 pack-years)

CYP1A1

No mutated28411.001.00
Mutated120.76 (0.06–8.90)1.12 (0.09–13.94)

mEH (139 )

His/His20581.001,00
His/Arg8241.06 (0.40–2.78)1.08 (0.37–3.13)
Arg/arg111.91 (0.11–33.10)2.82 (0.15–52.41)

GSTM1

Present17431.001.00
Absent12400.74 (0.31–1.76)0.88 (0.34–2.34)

Heavy smokers (>35 pack-years)

CYP1A1

No mutated23621.001.00
Mutated01

mEH (139 )

His/His43301.001.00
His/Arg17170.94 (0.39–2.26)0.68 (0.25–1.86)
Arg/arg30

GSTM1

Present28251.001.00
Absent35221.50 (0.67–1.33)1.40 (0.57–3.43)

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.